companies / inflam-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-05 json
| total_raised | 13,200,00013.2M | ○ |
|---|---|---|
| founded | null | |
| hq | Newton, MA | |
| industry | unknown | |
| stage | null |
Inflammasome Therapeutics develops drug therapies that target inflammasome activation to treat degenerative diseases. The company focuses on patients with ophthalmological conditions like geographic atrophy and neurological disorders such as Alzheimer's and ALS. It pursues a single biological pathway across multiple indications rather than disease-specific mechanisms.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2026-02-27 | Funding round | 13,200,00013.2M | null | ○ |
PHP 8.0.30, Apache HTTP Server, Modernizr, jQuery Migrate, WOW, Bootstrap, jquery 1.12.4, apache
| fact | status | src |
|---|---|---|
| Funding round, $13.2M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-09-25latest_round: seed, $13.2M, 2026-02-27 → Funding round, $13.2M, 2026-02-27, ○ 2026-05-05 | latest_round | seed, $13.2M, 2026-02-27 → Funding round, $13.2M, 2026-02-27 | ○ 2026-05-05 |
Records begin 2026-09-24. all_changes